| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,510 | 21,550 | 20:50 | |
| 21,510 | 21,550 | 20:50 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 28,000 | 120 | |||
| 27,650 | 80 | |||
| 22,500 | 280 | |||
| 21,780 | 376 | |||
| 21,630 | 105 | |||
| 21,610 | 105 | |||
| 21,590 | 378 | |||
| 21,560 | 1.045 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/gs71.htm [/URL] | ||||
| 1.045 | 21,520 | |||
| 378 | 21,480 | |||
| 105 | 21,460 | |||
| 105 | 21,440 | |||
| 376 | 21,310 | |||
| 140 | 21,100 | |||
| 10 | 18,990 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.159 | 1,153 | 2.489 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:50 | 21,560 | 438 |
| 17:24:05 | 21,530 | 1 |
| 17:23:38 | 21,530 | 248 |
| 17:20:41 | 21,540 | 9 |
| 15:47:50 | 21,510 | 142 |
| 15:40:56 | 21,430 | 14 |
| 15:26:04 | 21,350 | 792 |
| 15:26:04 | 21,350 | 1.195 |
| 15:26:04 | 21,350 | 80 |
| 15:25:06 | 21,340 | 345 |
| 15:20:00 | 21,390 | 1.506 |
| 15:19:45 | 21,400 | 359 |
| 15:19:45 | 21,400 | 302 |
| 15:12:43 | 21,400 | 573 |
| 15:12:39 | 21,420 | 7 |
| 15:10:04 | 21,420 | 46 |
| 15:03:38 | 21,400 | 59 |
| 14:58:51 | 21,380 | 7 |
| 14:53:21 | 21,370 | 134 |
| 14:52:27 | 21,370 | 26 |
| Tagesumsatz Xetra | -0,070 -0,32 % | 41.245 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:24 | Broker tips: AstraZeneca, GSK, Oxford Instruments | 7 | Sharecast | ||
| 14:54 | GSK signs agreement with Protas to streamline clinical trials | 3 | PMLiVE | ||
| GSK Aktie jetzt für 0€ handeln | |||||
| 12:58 | GSK: RSV-Impfstoff Arexvy in Japan nun auch für jüngere Risikogruppen zugelassen | 2 | Investing.com Deutsch | ||
| 12:30 | GSK plc - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 09:55 | GSK's RSV vaccine Arexvy approved in Japan for some adults under 50 | 5 | Alliance News |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:06 | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End | GlobeNewswire (Europe) | Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE... ► Artikel lesen | |
| 15:45 | MPH Health Care schlägt Dividende von 5,00 Euro je Aktie vor | 4investors | Der Aufsichtsrat der MPH Health Care AG hat den Jahresabschluss und den Konzernabschluss für das Geschäftsjahr 2025 gebilligt und damit festgestellt. Vorstand und Aufsichtsrat schlagen der Hauptversammlung... ► Artikel lesen | |
| 15:06 | Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development | PR Newswire | Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra.Sofdra... ► Artikel lesen | |
| 14:42 | Morning Market Movers: Sunshine Biopharma, GeoVax Labs, Huachen AI Parking Management Technology, LiveRamp See Big Swings | AFX News | BEIJING (dpa-AFX) - At 8:15 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 15:42 | Bayer Gets FDA Priority Review For Hyrnuo In First-Line HER2-Mutated Lung Cancer | AFX News | LEVERKUSEN (dpa-AFX) - Bayer AG (BYR.L) on Monday said the U.S. Food and Drug Administration has granted priority review for Hyrnuo as a first-line treatment for HER2-mutated non-small cell... ► Artikel lesen |